The use of rFVIIa in non-haemophilia bleeding conditions in paediatrics. A systematic review.
From its original envisioned use in patients with hemophilia and inhibitors, recombinant factor VIIa has been increasingly used in a variety of non-hemophilia bleeding/hemorrhagic situations with great efficacy. Most of the reported work has been in adult patients. This paper sets out to review its use in the pediatric non-hemophilia patients and the varied conditions it has been tried and used. Most of the published literature has shown that this agent is efficacious, safe and can be used as an adjunctive measure in the achievement of hemostasis. However, most of the published work is mainly anecdotal, case reports or small series. Randomized trials in children are eagerly awaited.
Mathew
Prasad
P
University of New Mexico, Department of Pediatrics, MSC 10 5590, 1 University of New Mexico, Albuquerque, New Mexico, 87131-0001, USA. pmathew@salud.unm.edu.
D001778:Blood Coagulation Disorders / Q000188:drug therapy; D002648:Child; D005167:Factor VII / Q000627:therapeutic use*; D005168:Factor VII Deficiency / Q000188:drug therapy; D015942:Factor VIIa; D006470:Hemorrhage / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007231:Infant, Newborn; D008107:Liver Diseases / Q000188:drug therapy; D011994:Recombinant Proteins / Q000627:therapeutic use*; D016896:Treatment Outcome; D014947:Wounds and Injuries / Q000188:drug therapy
D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa